Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8709229 | 1.00 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL6710932 | 0.96 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL6710934 | 0.96 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL6709446 | 0.75 | SMN1; SMN2 (0.43) | ALDH1A1SMN1; SMN2LMNATSHR | |
| SCHEMBL6443600 | 0.75 | SMN1; SMN2 (0.43) | ALDH1A1SMN1; SMN2LMNATSHR | |
| SCHEMBL27488208 | 0.75 | SLC6A3 (0.45) | ALDH1A1SLC6A3SLC6A2SLC6A4DHFR | |
| Hydrochloric Acid SCHEMBL7423286 | 0.73 | SLC6A3 (0.44) | ALDH1A1SLC6A3SLC6A2SLC6A4LMNA | |
| SCHEMBL9830051 | 0.73 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL9830054 | 0.73 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL27861451 | 0.71 | SLC6A3 (0.40) | ALDH1A1SLC6A3SLC6A2SLC6A4DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | ALDH1A1 889/4885SMN1; SMN2 1200/4885SLC6A3 2867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.